The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia
Abstract
BACKGROUND: Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells. Dexrazoxane, a free-radical scavenger, may protect the heart from doxorubicin-associated damage. METHODS: To determine whether dexrazoxane decreases doxorubicin-associated injury of cardiomyocytes, we randomly assigned 101 children with ALL to receive doxorubicin alone (30 mg per square meter of body-surface area every three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediately by doxorubicin. Serial measurements of serum cardiac troponin T were obtained in 76 of 101 patients in the doxorubicin group and 82 of 105 patients in the group given dexrazoxane and doxorubicin. A total of 2377 serum samples (mean, 15.1 samples per patient) were obtained before, during, and after treatment with doxorubicin. Troponin T levels were evaluated in a blinded fashion to determine whether they were elevated (>0.01 ng per milliliter)--the primary end point--or extremely elevated (>0.025 ng per milliliter). RESULTS: Elevations of troponin T occurred in 35 percent of the patients (55 of 158). Patients treated with doxorubicin alone were more likely than those who received dexrazoxane and doxorubicin to have elevated troponin T levels (50 percent vs. 21 percent, P<0.001) and extremely elevated troponin T levels (32 percent vs. 10 percent, P<0.001). The median follow-up was 2.7 years. The rate of event-free survival at 2.5 years was 83 percent in both groups (P=0.87 by the log-rank test). CONCLUSIONS: Dexrazoxane prevents or reduces cardiac injury, as reflected by elevations in troponin T, that is associated with the use of doxorubicin for childhood ALL without compromising the antileukemic efficacy of doxorubicin. Longer follow-up will be necessary to determine the influence of dexrazoxane on echocardiographic findings at four years and on event-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
Plackett, R. L., & Cox, D. R. (1971) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344247 · Cited by 2,264
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Self-citationSilverman, L. B. (2001) · Blood · doi:10.1182/blood.v97.5.1211 · Cited by 865
Self-citationLipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Self-citationMertens, A. C., Yasui, Y., Neglia, J. P., Potter, J. D., Nesbit, M. E., Ruccione, K., Smithson, W. A., & Robison, L. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3163 · Cited by 798
Morrow, D. A. (2001) · JAMA · doi:10.1001/jama.286.19.2405 · Cited by 656
Krischer, J. P., Epstein, S., Cuthbertson, D. D., Goorin, A. M., Epstein, M. L., & Lipshultz, S. E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1544 · Cited by 476
Self-citation
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Treatment of Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,976
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,795
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,414
Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010) · Cardiology · doi:10.1159/000265166 · Cited by 1,065
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeu192 · Cited by 1,058
Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.023 · Cited by 1,031
“For patients undergoing anthracycline-based ChT, concomitant dexrazoxane use may also be considered.(76,165,166) Although BBs, especially carvedilol in combination with ACEIs, have been shown to have a cardioprotective effect in preventing anthracycline-induced cardiomyopathy, when used for primary prevention,(67,70)…”
Anthracycline Chemotherapy and Cardiotoxicity
McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6711-0 · Cited by 956
Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., Hagerty, K. L., Somerfield, M. R., & Vaughn, D. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.9777 · Cited by 793
Late cardiotoxicity after treatment for Hodgkin lymphoma
Aleman, B. M. P., van den Belt-Dusebout, A. W., De Bruin, M. L., van 't Veer, M. B., Baaijens, M. H. A., Boer, J. P. D., Hart, A. A. M., Klokman, W. J., Kuenen, M. A., Ouwens, G. M., et al. (2007) · Blood · doi:10.1182/blood-2006-07-034405 · Cited by 746
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.121 · Cited by 727
Self-citationCardiotoxicity of anticancer treatments: Epidemiology, detection, and management
Curigliano, G., Cardinale, D., Dent, S., Criscitiello, C., Aseyev, O., Lenihan, D., & Cipolla, C. M. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21341 · Cited by 723
Kavey, R.-E. W., Allada, V., Daniels, S. R., Hayman, L. L., McCrindle, B. W., Newburger, J. W., Parekh, R. S., & Steinberger, J. (2006) · Circulation · doi:10.1161/circulationaha.106.179568 · Cited by 707
Weintraub, R. G., Semsarian, C., & Macdonald, P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31713-5 · Cited by 649
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Moslehi, J. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1100265 · Cited by 635
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Self-citationArmenian, S. H., Hudson, M. M., Mulder, R. L., Chen, M. H., Constine, L. S., Dwyer, M., Nathan, P. C., Tissing, W. J. E., Shankar, S., Sieswerda, E., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70409-7 · Cited by 570
Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy
Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., & Oliveira, P. J. (2014) · Medicinal Research Reviews · doi:10.1002/med.21280 · Cited by 569
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub4 · Cited by 553
Drug-induced mitochondrial dysfunction and cardiotoxicity
Varga, Z. V., Ferdinandy, P., Liaudet, L., & Pacher, P. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00554.2015 · Cited by 531
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Kalyanaraman, B. (2013) · Redox Biology · doi:10.1016/j.redox.2013.01.014 · Cited by 502
Cardiac side-effects of cancer chemotherapy
Monsuez, J.-J., Charniot, J.-C., Vignat, N., & Artigou, J.-Y. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.03.003 · Cited by 467
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Self-citationLipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Self-citationLipshultz, S. E., Law, Y. M., Asante-Korang, A., Austin, E. D., Dipchand, A. I., Everitt, M. D., Hsu, D. T., Lin, K. Y., Price, J. F., Wilkinson, J. D., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000682 · Cited by 416
Self-citationEschenhagen, T., Force, T., Ewer, M. S., de Keulenaer, G. W., Suter, T. M., Anker, S. D., Avkiran, M., de Azambuja, E., Balligand, J.-L., Brutsaert, D. L., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq213 · Cited by 413
Moghrabi, A., Levy, D. E., Asselin, B., Barr, R., Clavell, L., Hurwitz, C., Samson, Y., Schorin, M., Dalton, V. K., Lipshultz, S. E., et al. (2007) · Blood · doi:10.1182/blood-2006-06-027714 · Cited by 403
Self-citationPharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
Visscher, H., Ross, C. J. D., Rassekh, S. R., Barhdadi, A., Dubé, M.-P., Al-Saloos, H., Sandor, G. S., Caron, H. N., van Dalen, E. C., Kremer, L. C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3467 · Cited by 401
Anthracycline associated cardiotoxicity in survivors of childhood cancer
Lipshultz, S. E., Alvarez, J. A., & Scully, R. E. (2008) · Heart · doi:10.1136/hrt.2007.136093 · Cited by 379
Self-citationChemotherapy resistance in osteosarcoma: current challenges and future directions
Chou, A. J., & Gorlick, R. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.1075 · Cited by 377
Cardiotoxicity of Cancer Therapy
Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., & Perry, M. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.789 · Cited by 372
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Alvi, R. M., Frigault, M. J., Fradley, M. G., Jain, M. D., Mahmood, S. S., Awadalla, M., Lee, D. H., Zlotoff, D. A., Zhang, L., Drobni, Z. D., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.038 · Cited by 356
Kalam, K., & Marwick, T. H. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.030 · Cited by 343
Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115725 · Cited by 334
Štěrba, M., Popelová, O., Vávrová, A., Jirkovský, E., Kovaříková, P., Geršl, V., & Šimůnek, T. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4795 · Cited by 329
Lipshultz, S. E., Miller, T. L., Scully, R. E., Lipsitz, S. R., Rifai, N., Silverman, L. B., Colan, S. D., Neuberg, D. S., Dahlberg, S. E., Henkel, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3404 · Cited by 323
Self-citationSilverman, L. B., Stevenson, K. E., O'Brien, J. E., Asselin, B. L., Barr, R. D., Clavell, L., Cole, P. D., Kelly, K. M., Laverdiere, C., Michon, B., et al. (2010) · Leukemia · doi:10.1038/leu.2009.253 · Cited by 316
Self-citationCancer survivorship research: State of knowledge, challenges and opportunities
Aziz, N. M. (2007) · Acta Oncologica · doi:10.1080/02841860701367878 · Cited by 310
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1039 · Cited by 307
Self-citationShankar, S. M., Marina, N., Hudson, M. M., Hodgson, D. C., Adams, M. J., Landier, W., Bhatia, S., Meeske, K., Chen, M. H., Kinahan, K. E., et al. (2008) · Pediatrics · doi:10.1542/peds.2007-0575 · Cited by 283
Mechanisms of Anthracycline Cardiac Injury: Can We Identify Strategies for Cardioprotection?
Sawyer, D. B., Peng, X., Chen, B., Pentassuglia, L., & Lim, C. C. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.06.007 · Cited by 270
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243
Self-citationZhao, L., Tao, X., Qi, Y., Xu, L., Yin, L., & Peng, J. (2018) · Redox Biology · doi:10.1016/j.redox.2018.02.026 · Cited by 202
Doxorubicin‐Induced Cardiomyopathy in Children
Mancilla, T. R., Iskra, B., & Aune, G. J. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180017 · Cited by 108
Iron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications
Rao, V. A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4877 · Cited by 37
Heart transplantation in survivors of childhood cancer
Shugh, S. B., & Ryan, T. D. (2019) · Translational Pediatrics · doi:10.21037/tp.2019.06.02 · Cited by 13
Metadata
- Authors
- Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., Gelber, R. D., & Sallan, S. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-07-08
- Volume
- 351
- Issue
- 2
- Pages
- 145-153
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2084196088
- Cited by
- 623
- References
- 34
- FWCI
- 23.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.